Pharmaceutical Company Outlook to 2014

PharmaVitae universe Rx sales are forecast to expand at a 2008-14 CAGR of 1.2%, down 9.3 percentage points from 2002-08. The underlying cause of this falling rate is the much-discussed genericization of small molecule products. However, not all sectors are equally exposed, prompting a shake-up of the industry and an increasing pursuit of cost savings to sustain operating profit growth rates.

Pharmaceutical Licensing Overview - Risk-aversion breeds creativity as externalization intensifies

Big Pharma continues to restructure its internal R&D departments as part of widespread cost-cutting measures to help reduce the impact of the impending 2011 patent cliff. To fill pipeline voids with new products, companies continue to make acquisitions and form partnerships with small pharma, biotech companies and academia, although the relationships between each are becoming increasingly dynamic.

Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline

GBI Research's new report "Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline" provides an insight into the global biotechnology industry and analyses the competitive positioning of the top 10 companies in the industry. The report estimates the market size of the global biotechnology industry and its future prospects. It benchmarks the leading companies in the biotechnology industry on selected parameters to analyze their competitive positioning in the market. The future landscape of the biotechnology industry is also analysed by forecasting the revenues of leading companies till 2012. For each company this report analyses the financial strength, product portfolio, pipeline strength and therapeutic focus of its R&D activities. It critically examines the strengths and weaknesses of individual companies and the opportunities and threats facing them.

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!

Daiichi Sankyo Co., Ltd: PharmaVitae Profile

This analysis examines the historical and forecast performance for Daiichi Sankyo in the Rx pharmaceutical sector.

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!

F. Hoffmann-La Roche Ltd.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Roche in the prescription pharmaceutical sector.

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!

Pharmaceutical Company Outlook to 2014

PharmaVitae universe Rx sales are forecast to expand at a 2008-14 CAGR of 1.2%, down 9.3 percentage points from 2002-08. The underlying cause of this falling rate is the much-discussed genericization of small molecule products. However, not all sectors are equally exposed, prompting a shake-up of the industry and an increasing pursuit of cost savings to sustain operating profit growth rates.

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!

Sanofi-Aventis: PharmaVitae Profile

This analysis examines the historical and forecast performance for Sanofi-Aventis in the pharmaceutical sector.

Genzyme Corporation: PharmaVitae Profile

This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector.